Table 2.
Clinical characteristics and STAS of patients with stage I NSCLC after PSM
| Variable | PNB (n = 38) | Non-biopsy (n = 38) | P-value | BB (n = 28) | Non-biopsy (n = 28) | P-value |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Female | 20(52.6) | 22(57.9) | 0.645 | 6(21.4) | 8(28.6) | 0.537 |
| Male | 18(47.4) | 16(42.1) | 22(78.6) | 20(71.4) | ||
| Age | 62.61 ± 9.00 | 59.24 ± 7.56 | 0.081 | 63.11 ± 8.412 | 63.07 ± 8.08 | 0.987 |
| Smoking history | ||||||
| No | 25(65.8) | 27(71.1) | 0.622 | 9(32.1) | 9(32.1) | 1.000 |
| Yes | 13(34.2) | 11(28.9) | 19(67.9) | 19(67.9) | ||
| Tumor location | ||||||
| Peripheral | 35(92.1) | 38(100.0) | 0.240* | 9(32.1) | 9(32.1) | 1.000 |
| Central | 3(7.9) | 0(0.0) | 19(67.9) | 19(67.9) | ||
| Scope of surgery | ||||||
| Lobectomy | 37(97.4) | 38(100.0) | 1.000* | 27(96.4) | 26(92.9) | 1.000* |
| Sublobar resection | 1(2.6) | 0(0.0) | 1(3.6) | 2(7.1) | ||
| Pathological type | ||||||
| Adenocarcinoma | 32(84.2) | 35(92.1) | 0.432 | 7(25.0) | 9(32.1) | 0.554# |
| Squamous carcinoma | 4(10.5) | 1(2.6) | 21(75.0) | 19(67.9) | ||
| Other | 2(5.3) | 2(5.3) | 0(0.0) | 0(0.0) | ||
| Staging | ||||||
| Stage Ia | 17(44.7) | 15(39.5) | 0.642 | 15(53.6) | 13(46.4) | 0.593 |
| Stage Ib | 21(55.3) | 23(60.5) | 13(46.4) | 15(53.6) | ||
| Maximum tumor diameter | 2.26 ± 0.84 | 1.93 ± 0.71 | 0.074 | 2.68 ± 1.04 | 2.53 ± 0.87 | 0.571 |
| Postoperative adjuvant therapy | ||||||
| No | 20(52.6) | 19(50.0) | 0.818 | 14(50.0) | 11(39.3) | 0.420 |
| Yes | 18(47.4) | 19(50.0) | 14(50.0) | 17(60.7) | ||
NSCLC non-small cell lung cancer, PSM propensity score matching, PNB percutaneous needle biopsy, BB bronchoscopic biopsy, STAS tumor spread through air spaces
#Because the Others in both groups are 0, the 2 × 2 chi-square test was performed after deleting this item
*Using Fisher’s exact test